Hanall Biopharma Co., Ltd. (KRX:009420)

Hanall Biopharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	13,550	16,386	33,723	16,841	12,794	4,200
Short-Term Investments	-	-	-	10,000	-	-
Trading Asset Securities	-	8,320	22,775	27,093	67,775	86,505
Cash & Short-Term Investments	13,550	24,706	56,497	53,934	80,570	90,706
Cash Growth	-71.88%	-56.27%	4.75%	-33.06%	-11.18%	-4.95%
Accounts Receivable	13,896	15,335	15,630	26,689	9,861	11,553
Other Receivables	2,656	4,735	6,894	4,021	5,694	4,175
Receivables	16,552	20,069	22,524	30,709	15,555	15,729
Inventory	40,628	37,702	32,384	25,184	20,408	19,891
Prepaid Expenses	249.92	106.93	93.41	126.5	141.46	142.88
Other Current Assets	3,228	2,769	2,078	1,835	2,141	2,896
Total Current Assets	74,208	85,353	113,577	111,789	118,815	129,365
Property, Plant & Equipment	18,363	18,517	19,434	19,126	19,045	15,480
Long-Term Investments	33,459	44,134	59,626	39,315	23,990	52,779
Other Intangible Assets	55,410	4,537	1,826	2,063	2,219	2,597
Long-Term Accounts Receivable	-	-	-	0	-0	-0
Long-Term Deferred Tax Assets	11,059	9,469	6,978	8,549	12,220	3,203
Long-Term Deferred Charges	-	47,274	30,783	21,776	16,877	12,481
Other Long-Term Assets	2,915	3,292	7,512	10,833	5,312	4,228
Total Assets	195,719	212,881	239,747	213,451	198,478	220,132
Accounts Payable	4,181	10,679	11,273	4,755	1,759	4,946
Accrued Expenses	2,223	2,297	3,039	2,123	2,147	2,105
Current Portion of Leases	840.51	748.15	700.22	559.34	423.43	274.76
Current Income Taxes Payable	-	-	356.7	919.83	94.87	818.23
Other Current Liabilities	20,692	20,996	22,284	20,178	17,695	14,925
Total Current Liabilities	27,936	34,720	37,652	28,535	22,120	23,069
Long-Term Leases	770.45	699.66	590.31	751.06	911.68	276.76
Other Long-Term Liabilities	6,538	8,705	15,286	15,909	11,954	15,513
Total Liabilities	36,414	44,529	53,529	45,195	34,986	38,859
Common Stock	26,120	26,120	26,120	26,120	26,120	26,120
Additional Paid-In Capital	118,648	116,768	115,040	112,800	112,777	112,489
Retained Earnings	26,285	26,492	31,362	29,409	26,379	17,587
Treasury Stock	-13,606	-12,587	-13,205	-13,228	-3,254	-3,339
Comprehensive Income & Other	1,859	11,558	26,902	13,156	1,469	28,416
Shareholders' Equity	159,305	168,351	186,218	168,256	163,492	181,273
Total Liabilities & Equity	195,719	212,881	239,747	213,451	198,478	220,132
Total Debt	1,611	1,448	1,291	1,310	1,335	551.51
Net Cash (Debt)	11,939	23,259	55,207	52,624	79,234	90,154
Net Cash Growth	-74.51%	-57.87%	4.91%	-33.59%	-12.11%	-4.97%
Net Cash Per Share	235.28	458.63	1089.06	1035.58	1547.46	1761.59
Filing Date Shares Outstanding	50.79	50.77	50.69	50.69	51.21	51.18
Total Common Shares Outstanding	50.79	50.77	50.69	50.69	51.21	51.18
Working Capital	46,272	50,633	75,925	83,254	96,695	106,295
Book Value Per Share	3136.41	3316.25	3673.44	3319.29	3192.82	3541.94
Tangible Book Value	103,895	163,815	184,392	166,193	161,273	178,676
Tangible Book Value Per Share	2045.50	3226.89	3637.42	3278.59	3149.48	3491.19
Land	-	1,494	1,494	1,494	1,494	1,494
Buildings	-	17,467	17,417	17,363	14,968	14,694
Machinery	-	14,021	16,638	16,546	14,294	14,997
Construction In Progress	-	235.96	514.54	101.28	3,603	18.98

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.